Clinical Trials
31 trialsVR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma
Henan Cancer Hospital
Linperlisib Combined With Chidamide in Patients With PTCL
Henan Cancer Hospital
R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma
Henan Cancer Hospital
Allogeneic CD7 CAR γδ T Cells Therapy Recurrent/Refractory Leukemia
Anhui Provincial Hospital
Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma
Henan Cancer Hospital
PTCy and ATG for MSD and MUD Transplants
Instituto Nacional de Cancer, Brazil
SCRIPT-AML
Vastra Gotaland Region
First-line Gemcitabine Plus Cisplatin in Locally Advanced (IIIC Stage) Breast Cancer Patients
The National Center of Oncology, Azerbaijan
Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients
The Affiliated People's Hospital of Ningbo University
The Safety and Efficacy of Double-target CART-19 and 20 Cells in Non-Hodgkin's Lymphoma (NHL)
Henan Cancer Hospital
QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Anhui Provincial Hospital
Allogeneic γ9δ2 T Cells Treatment of Recurrent Hematologic Tumors
Anhui Provincial Hospital
Go-CHOP as the Frontline Therapy for PTCL
Henan Cancer Hospital
Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients
Sheba Medical Center
TIL Cells for the Treatment of the Advanced Solid Tumors Patients
Fujian Cancer Hospital
TCR-T Cells for the Treatment NY-ESO-1-positive Advanced Solid Tumors
Fujian Cancer Hospital
Assessment of Safety and Efficacy of ThisCART19A in Adult Patients With B Cell Malignancies After Failure of Autologous Chimeric Antigen Receptor T- Cell(CAR-T) Therapy
Henan Cancer Hospital
Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies
The Affiliated People's Hospital of Ningbo University
EBV-TCR-T(YT-E001)for Patients With EBV-positive Recurrent or Metastatic NPC
Fujian Cancer Hospital
Neoadjuvant Hormonal Therapy Compared to Neoadjuvant Chemotherapy in Stage IIIB/C and IV Breast Cancer Patients
Dharmais National Cancer Center Hospital
MM-POM-2018
Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado
Improved Post-Transplant Cyclophosphamide Regimens for Pediatric Patients With Refractory AML
Capital Research Institute of Pediatrics
NeoChAI
National Cancer Center, Korea
The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL).
Henan Cancer Hospital
Study of BCMA CAR-T in Multiple Myeloma
Henan Cancer Hospital
CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.
Henan Cancer Hospital
ZoNantax - Zolendronic Acid as Neoadjuvant Therapy Plus Anthracycline and Taxane in Locally Advanced Breast Cancer
Instituto Nacional de Cancer, Brazil
The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma
Henan Cancer Hospital
Primary Chemotherapy With Adriamycin/Cyclophosphamide(AC) vs Taxotere/Xeloda(TX) for Stage II and III Breast Cancer
National Cancer Center, Korea
Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT)
Tel-Aviv Sourasky Medical Center
EpSSG (European Soft Tissue Sarcoma Study Group) Protocol for Non-Metastatic Rhabdomyosarcoma in Children
Sheba Medical Center